KRAS and malignant colon neoplasm: Mutant forms of drug targets (e.g., mutations of EGFR, such as L858R or T790M in circulating EVs may suggest either sensitivity or resistance to EGFR inhibitors, respectively; EV-associated mutant K-ras in colon cancer could be linked to resistance to cetuximab)